A Phase 1, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a phase 1 / 2 open label multicenter study to evaluate the maximum tolerance, safety,
tolerance and PK of oral yy-15293 in patients with advanced solid tumors with KRAS G12C
mutation, so as to confirm the recommended phase 2 dose of yy-15293 and obtain the
preliminary efficacy information of patients with advanced solid tumors with KRAS G12C
mutation.